T1	CHEM 29 39	calcitriol
#1	AnnotatorNotes T1	C0006674; calcitriol; Organic Chemical · Pharmacologic Substance · Vitamin | C3714610; Calcitriol Drug Class; Pharmacologic Substance · Vitamin
T2	PROC 46 57	tratamiento
#2	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	DISO 62 92	hiperparatiroidismo secundario
#3	AnnotatorNotes T3	C0020503; Hyperparathyroidism, Secondary; Disease or Syndrome
T4	PROC 171 190	valorar la utilidad
T5	PROC 206 217	tratamiento
#4	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	DISO 294 324	hiperparatiroidismo secundario
#5	AnnotatorNotes T6	C0020503; Hyperparathyroidism, Secondary; Disease or Syndrome
T7	PROC 353 365	hemodiálisis
#6	AnnotatorNotes T7	C0019004; Hemodialysis; Therapeutic or Preventive Procedure
T8	CHEM 517 520	PTH
#7	AnnotatorNotes T8	C0020063; PTH protein, human; Amino Acid, Peptide, or Protein · Hormone | C0030520; parathyroid hormone; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T9	ANAT 521 527	sérica
#8	AnnotatorNotes T9	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T10	CHEM 685 695	calcitriol
#9	AnnotatorNotes T10	C0006674; calcitriol; Organic Chemical · Pharmacologic Substance · Vitamin | C3714610; Calcitriol Drug Class; Pharmacologic Substance · Vitamin
T11	PROC 717 731	niveles de PTH
#10	AnnotatorNotes T11	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T12	CHEM 898 908	calcitriol
#11	AnnotatorNotes T12	C0006674; calcitriol; Organic Chemical · Pharmacologic Substance · Vitamin | C3714610; Calcitriol Drug Class; Pharmacologic Substance · Vitamin
T13	PROC 932 935	PTH
#12	AnnotatorNotes T13	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T14	PROC 997 1000	PTH
#13	AnnotatorNotes T14	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T15	PROC 1026 1048	cesaban el tratamiento
#14	AnnotatorNotes T15	C0850893; stop medication; Therapeutic or Preventive Procedure
T16	PROC 1085 1087	Ca
#15	AnnotatorNotes T16	C0201925; Calcium measurement; Laboratory Procedure
T17	PROC 1093 1099	Ca × P
#16	AnnotatorNotes T17	C3641229; Calcium and Phosphorus Product Measurement; Laboratory Procedure
T18	PROC 1237 1246	protocolo
#17	AnnotatorNotes T18	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T19	PROC 1295 1304	protocolo
#18	AnnotatorNotes T19	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T20	PROC 1662 1665	PTH
#19	AnnotatorNotes T20	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T21	DISO 1774 1790	efectos adversos
#20	AnnotatorNotes T21	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T22	PROC 1895 1906	tratamiento
#21	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	DISO 1968 1998	hiperparatiroidismo secundario
#22	AnnotatorNotes T23	C0020503; Hyperparathyroidism, Secondary; Disease or Syndrome
T24	PROC 96 104	diálisis
#23	AnnotatorNotes T24	C0011946; Dialysis procedure; Therapeutic or Preventive Procedure | C4551529; Renal Dialysis; Therapeutic or Preventive Procedure
T25	CHEM 222 232	calcitriol
#24	AnnotatorNotes T25	C0006674; calcitriol; Organic Chemical · Pharmacologic Substance · Vitamin | C3714610; Calcitriol Drug Class; Pharmacologic Substance · Vitamin
T26	PROC 443 446	PTH
#25	AnnotatorNotes T26	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T27	PROC 517 527	PTH sérica
#26	AnnotatorNotes T27	C0428408; Serum parathyroid hormone measurement; Laboratory Procedure
T28	PROC 541 543	Ca
#27	AnnotatorNotes T28	C0201925; Calcium measurement; Laboratory Procedure
T29	PROC 575 581	Ca × P
#28	AnnotatorNotes T29	C3641229; Calcium and Phosphorus Product Measurement; Laboratory Procedure
T30	PROC 625 628	PTH
#29	AnnotatorNotes T30	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T31	CHEM 728 731	PTH
#30	AnnotatorNotes T31	C0020063; PTH protein, human; Amino Acid, Peptide, or Protein · Hormone | C0030520; parathyroid hormone; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T32	PROC 742 745	PTH
#31	AnnotatorNotes T32	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T33	PROC 773 776	PTH
#32	AnnotatorNotes T33	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T34	PROC 806 809	PTH
#33	AnnotatorNotes T34	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T35	PROC 840 843	PTH
#34	AnnotatorNotes T35	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T36	PROC 1365 1381	régimen de dosis
#35	AnnotatorNotes T36	C2348331; Dose Regimen; Therapeutic or Preventive Procedure
T37	PROC 1594 1597	PTH
#36	AnnotatorNotes T37	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T38	PROC 1737 1740	PTH
#37	AnnotatorNotes T38	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T39	CHEM 1911 1921	calcitriol
#38	AnnotatorNotes T39	C0006674; calcitriol; Organic Chemical · Pharmacologic Substance · Vitamin | C3714610; Calcitriol Drug Class; Pharmacologic Substance · Vitamin
T40	Duration 119 129	seis meses
T41	LIVB 340 349	pacientes
#39	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	Duration 424 438	los seis meses
T45	LIVB 592 601	pacientes
#40	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T46	Dose 755 761	0,5 µg
T47	Dose 786 794	1-1,5 µg
T48	Dose 857 863	2-3 µg
T49	Dose 919 925	al 50%
T52	LIVB 1016 1025	pacientes
#41	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T54	LIVB 1193 1202	pacientes
#42	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T43	Dose 819 827	1,5-2 µg
T44	Neg_cue 1383 1385	no
T50	Neg_cue 1495 1497	no
T51	Neg_cue 1799 1801	no
T53	Observation 1386 1397	cumplidores
#43	AnnotatorNotes T53	C2364172; Adherence To Medication Regime; Finding
R1	Negation Arg1:T44 Arg2:T53	
A1	Assertion T53 Negated
T55	Observation 1802 1813	cumplidores
A2	Assertion T55 Negated
#44	AnnotatorNotes T55	C2364172; Adherence To Medication Regime; Finding
R2	Negation Arg1:T51 Arg2:T55	
T56	Observation 1498 1509	cumplidores
A3	Assertion T56 Negated
#45	AnnotatorNotes T56	C2364172; Adherence To Medication Regime; Finding
R3	Negation Arg1:T50 Arg2:T56	
T57	Neg_cue 1628 1634	ningún
T58	Observation 1648 1665	incremento de PTH
A4	Assertion T58 Negated
#46	AnnotatorNotes T58	C0748089; Parathyroid hormone concentration above normal range; Finding
R4	Negation Arg1:T57 Arg2:T58	
T59	Neg_cue 1333 1341	falta de
T60	Observation 1351 1381	adherencia al régimen de dosis
A5	Assertion T60 Negated
#47	AnnotatorNotes T60	C2364172; Adherence To Medication Regime; Finding
T61	Observation 1697 1710	incumplidores
A6	Assertion T61 Negated
#48	AnnotatorNotes T61	C0746935; Medication Nonadherence; Finding
T62	PROC 1 25	Optimización de la dosis
#49	AnnotatorNotes T62	C1273380; Optimization of drug dosage; Therapeutic or Preventive Procedure
R5	Used_for Arg1:T1 Arg2:T2	
R6	Used_for Arg1:T1 Arg2:T62	
R8	Used_for Arg1:T25 Arg2:T5	
T63	CONC 237 242	dosis
#50	AnnotatorNotes T63	C0178602; Dosage; Quantitative Concept
R9	Has_Dose_or_Strength Arg1:T25 Arg2:T63	
T64	Result_or_Value 253 289	proporcionales al grado de severidad
R10	Has_Result_or_Value Arg1:T63 Arg2:T64	
T65	Quantifier_or_Qualifier 243 252	iniciales
#51	AnnotatorNotes T65	C0205265; Initially; Temporal Concept
R11	Has_Quantifier_or_Qualifier Arg1:T63 Arg2:T65	
R12	Experiences Arg1:T41 Arg2:T7	
R13	Overlap Arg1:T26 Arg2:T42	
R14	Location_of Arg1:T9 Arg2:T27	
T66	Result_or_Value 528 539	> 285 pg/mL
R15	Has_Result_or_Value Arg1:T27 Arg2:T66	
T67	Result_or_Value 544 556	< 10,5 mg/dl
R16	Has_Result_or_Value Arg1:T28 Arg2:T67	
T68	Result_or_Value 582 586	< 60
R17	Has_Result_or_Value Arg1:T29 Arg2:T68	
R20	Experiences Arg1:T45 Arg2:T30	
R21	Experiences Arg1:T45 Arg2:T10	
R22	Experiences Arg1:T45 Arg2:T11	
R23	Experiences Arg1:T45 Arg2:T32	
R24	Has_Dose_or_Strength Arg1:T10 Arg2:T46	
R25	Has_Dose_or_Strength Arg1:T10 Arg2:T47	
R18	Experiences Arg1:T45 Arg2:T33	
R19	Experiences Arg1:T45 Arg2:T34	
R26	Experiences Arg1:T45 Arg2:T35	
R27	Has_Dose_or_Strength Arg1:T10 Arg2:T43	
R28	Has_Dose_or_Strength Arg1:T10 Arg2:T48	
R29	Has_Dose_or_Strength Arg1:T12 Arg2:T49	
T69	Observation 932 945	PTH disminuía
#52	AnnotatorNotes T69	C0856879; Parathyroid hormone decreased; Finding
T70	Observation 982 1000	descenso de la PTH
#53	AnnotatorNotes T70	C0856879; Parathyroid hormone decreased; Finding
R32	Before Arg1:T69 Arg2:T49	
R33	Before Arg1:T70 Arg2:T72	
T72	Dose 955 975	se incrementó un 50%
R34	Has_Dose_or_Strength Arg1:T12 Arg2:T72	
R35	Experiences Arg1:T52 Arg2:T15	
T71	Observation 1056 1077	excluidos del estudio
#54	AnnotatorNotes T71	C0422727; Patient withdrawn from trial; Finding (?)
R37	Before Arg1:T16 Arg2:T71	
R38	Before Arg1:T17 Arg2:T71	
R39	Experiences Arg1:T52 Arg2:T16	
R40	Experiences Arg1:T52 Arg2:T17	
T73	Observation 1248 1259	cumplidores
#55	AnnotatorNotes T73	C2364172; Adherence To Medication Regime; Finding
T74	Observation 1211 1223	cumplimiento
#56	AnnotatorNotes T74	C2364172; Adherence To Medication Regime; Finding
T75	Quantifier_or_Qualifier 1224 1232	estricto
R41	Has_Quantifier_or_Qualifier Arg1:T74 Arg2:T75	
R42	Negation Arg1:T59 Arg2:T60	
T76	Quantifier_or_Qualifier 1342 1350	estricta
R43	Has_Quantifier_or_Qualifier Arg1:T60 Arg2:T76	
R45	Has_Quantifier_or_Qualifier Arg1:T54 Arg2:T73	
T77	Observation 1280 1304	violaciones de protocolo
#57	AnnotatorNotes T77	C1709261; Non-Compliance With Study Drug; Finding (?)
R47	Overlap Arg1:T74 Arg2:T18	
R48	Overlap Arg1:T18 Arg2:T73	
R49	Overlap Arg1:T77 Arg2:T19	
R50	Overlap Arg1:T60 Arg2:T36	
R51	Overlap Arg1:T36 Arg2:T53	
T78	Observation 1410 1421	cumplidores
#58	AnnotatorNotes T78	C2364172; Adherence To Medication Regime; Finding
T79	Observation 1535 1546	cumplidores
#59	AnnotatorNotes T79	C2364172; Adherence To Medication Regime; Finding
T80	Observation 1582 1597	descenso de PTH
#60	AnnotatorNotes T80	C0856879; Parathyroid hormone decreased; Finding
R52	Overlap Arg1:T79 Arg2:T80	
R53	Overlap Arg1:T79 Arg2:T58	
T81	Observation 1711 1740	aumentaron sus niveles de PTH
#61	AnnotatorNotes T81	C0748089; Parathyroid hormone concentration above normal range; Finding
R54	Overlap Arg1:T61 Arg2:T81	
T82	Observation 1746 1757	cumplidores
#62	AnnotatorNotes T82	C2364172; Adherence To Medication Regime; Finding
R55	Overlap Arg1:T82 Arg2:T21	
R56	Overlap Arg1:T55 Arg2:T21	
R57	Used_for Arg1:T39 Arg2:T22	
T83	CONC 1930 1935	dosis
#63	AnnotatorNotes T83	C0178602; Dosage; Quantitative Concept
R58	Has_Dose_or_Strength Arg1:T39 Arg2:T83	
T84	Result_or_Value 1936 1963	proporcional a la severidad
R59	Has_Result_or_Value Arg1:T83 Arg2:T84	
T85	CONC 106 116	Resultados
#64	AnnotatorNotes T85	C1274040; Result; Functional Concept
R7	Overlap Arg1:T85 Arg2:T40	
R30	Has_Quantifier_or_Qualifier Arg1:T54 Arg2:T53	
A7	Experiencer T41 Patient
A8	Experiencer T45 Patient
A9	Experiencer T52 Patient
A10	Experiencer T54 Patient
R31	Has_Result_or_Value Arg1:T38 Arg2:T81	
R36	Has_Result_or_Value Arg1:T20 Arg2:T58	
R44	Has_Result_or_Value Arg1:T13 Arg2:T69	
R46	Has_Result_or_Value Arg1:T14 Arg2:T70	
R60	Has_Result_or_Value Arg1:T37 Arg2:T80	
